For a decade, the idea of "turning back the clock on cells" was considered science fiction. In 2026, it crosses the line into real medicine. Life Biosciences of Boston, founded by Harvard researcher David Sinclair, is launching this year the first-ever human clinical trial of "partial reprogramming," a method aimed at reversing cellular aging on demand.
What will happen in the trial?
The trial will include two groups of patients:
- Up to 12 people with glaucoma of a specific type
- Up to 6 people with NAION, an acute anterior optic nerve injury that usually results in blindness
Patients will receive a gene therapy injection in one eye only. Three of the four original Yamanaka factors will be introduced into cells, without c-Myc, which has been identified as the most dangerous oncogenic factor. The genes will be activated only when the patient takes doxycycline (an antibiotic from the tetracycline family used here as a switch to activate genes in the Tet-On system). Follow-up period: at least five years.
What are Yamanaka factors anyway?
In 2006, Japanese researcher Shinya Yamanaka discovered four genes that, when introduced into an adult cell, return it to a "stem cell" state, a young cell with the potential to become any tissue type. For this discovery, Yamanaka received the Nobel Prize in Medicine in 2012.
The problem: when all four factors are fully activated, the cell completely loses its identity and becomes a stem cell with a high risk of tumor growth. The breakthrough of "partial reprogramming" was the discovery that if the factors are activated in short pulses, the cell becomes younger but retains its tissue role.
The experiments that led here
Researcher Juan Carlos Izpisua Belmonte already demonstrated in 2016 that cyclic activation of Yamanaka factors extended the lifespan of mice with progeria (accelerated aging syndrome) and improved muscle and pancreas regeneration in normal aged mice. Following him, additional studies reported improved heart regeneration, skin renewal, and memory improvement in old mice.
Another researcher, Noah Davidson and his colleagues at Rejuvenate Bio, injected three Yamanaka factors into old mice, and the mice showed improvement in all health metrics and lived longer, without tumor formation. "We injected the mice, and honestly, we waited for them to die," Davidson said. "But they thrived."
Why specifically the eyes?
The eye was chosen as the first human target for two reasons:
- Biologically isolated. Any risk of tumor formation remains local and does not spread to the body
- Measurable. It is easy to assess success (vision tests) and track cellular changes
Additionally, diseases like NAION desperately need treatment: currently, there is no treatment that restores vision after such an acute injury.
Not just Life Biosciences
They are not alone in the race:
- Altos Labs, raised $3 billion from investors including Jeff Bezos
- Retro Biosciences, Sam Altman's (OpenAI) anti-aging company
- NewLimit, a company by Brian Armstrong (Coinbase)
- Shift Bioscience, based in Cambridge, UK
The risks and what is already known
"Studies in monkeys found no evidence of cancer or any other harmful effect from the procedure," summarizes Sharon Rosenzweig-Lipson, Sinclair's colleague at Life Biosciences.
But not all researchers are equally optimistic. "When cells lose their identity, we know that comes with certain types of danger," warns Tamir Chandra from the University of Edinburgh.
What does this mean for you?
In 2026, the treatment is still years away from you. This trial is only the first step: individual patients, specific diseases, 5-year follow-up. Even if it succeeds, it will likely take another 3-5 years before similar treatments receive FDA approval.
But the historical significance is immense. For the first time in the 21st century, science can turn back the cellular clock, not just slow it down.
💬 Comments (0)
Be the first to comment on the article.